-- Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8) at three months on setmelanotide therapy; mean BMI decrease of 21.3% in patients (n=5) who reached six months --
-- Greater reduction in fat mass (29.7%) versus reduction in lean muscle mass (7.7%) reported from Phase 2 trial extension in patients with acquired hypothalamic obesity (n=11) after 12 months --
-- Positive data from Phase 2 DAYBREAK stage 2 showed mean BMI reduction of 12.4% in patients with rare MC4R pathway diseases on continuous setmelanotide therapy for 40 weeks (n=32) --
-- New Phase 3 VENTURE trial data showed mean BMI reduction of 23.8% in pediatric patients aged 2 -